

**AMENDMENTS TO THE CLAIMS**

1. (currently amended): A method of treating Type I diabetes, comprising:  
administering a pharmaceutically effective amount of a p38 mitogen activated protein (MAP) kinase inhibitor sufficient to prevent treat or reduce symptoms associated with the onset of Type I diabetes, in a subject in need thereof, wherein the inhibitor inhibits the alpha isoform of p38 MAP kinase.
2. (original): The method of claim 1, wherein the subject presents an increased immune response against a heat shock protein.
3. (original): The method of claim 2, wherein the heat shock protein is HSP 60.
4. (currently amended): The method of claim 1, wherein said p38 MAP kinase inhibitor is a selective [[for]] inhibitor of the p38 $\alpha$ , p38 $\beta$ , p38 $\gamma$ , or p38 $\delta$  isoforms of p38 MAP kinase.
5. (previously presented): The method of claim 1, wherein said subject is a human.
6. (previously presented): The method of claim 1, wherein administration of the p38 MAP kinase inhibitor results in a decrease in blood glucose levels.
- 7-8. (canceled)
9. (previously presented): The method of claim 1, wherein administration of the p38 MAP kinase inhibitor results in an inhibition in body weight loss in the subject.
- 10-11. (canceled)